分子异质性与免疫浸润驱动上尿路尿路上皮癌的临床结局
对上尿路尿路上皮癌(UTUC)肿瘤行靶向DNA和全转录组RNA测序,用共识非负矩阵分解识别出5个分子簇,各簇临床结局不同;免疫丰富的C4和C5亚型虽复发率高、生存差,但利于免疫检查点阻断(ICB)应答,提示术后高转移复发风险患者最可能从围手术期ICB获益。
要点
- 100例UTUC肿瘤行靶向DNA和全转录组RNA测序,共识非负矩阵分解识别出5个分子簇。
- C1和C2为预后良好亚型,呈腔面样特征且肿瘤微环境(TME)免疫耗竭。
- C3以FGFR3改变和更高肿瘤突变负荷为特征,包含全部微卫星不稳定肿瘤。
核心结论
- RNA测序揭示了既往认识不足的UTUC分子异质性,提示术后转移复发风险最高的UTUC患者最可能从围手术期ICB获益。
研究设计与样本
- 对100例接受肾输尿管切除术患者的UTUC肿瘤行靶向DNA和全转录组RNA测序。
- 采用共识非负矩阵分解识别与临床结局相关的分子簇,并行基因集富集与免疫解卷积分析。
- 采用加权基因共表达网络分析对每个分子簇的基因网络进行无监督识别。
主要发现
- 识别出5个临床结局不同的分子簇。
- 预后良好亚型C1和C2以腔面样特征和免疫耗竭的肿瘤微环境为特征。
- 亚型C3以FGFR3改变和更高肿瘤突变负荷为特征,并包含全部微卫星不稳定肿瘤。
- 亚型C4和C5复发率更高、生存更差,但肿瘤微环境免疫丰富,利于ICB应答。
临床怎么用
- 作者认为,术后转移复发风险最高的UTUC患者最可能从围手术期ICB获益。
局限性
- 局限性包括将原发部位肿瘤的分子特征外推以判断全身免疫治疗应答。
- 局限性包括批量测序分辨率有限,难以区分肿瘤、间质和免疫 compartments 的基因表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed multi-omic analysis of UTUC tumors to identify molecular features associated with disease recurrence and response to immune checkpoint blockade (ICB). METHODS: Targeted DNA and whole transcriptome RNA sequencing was performed on 100 UTUC tumors collected from patients undergoing nephroureterectomy. Consensus non-negative matrix factorization was used to identify molecular clusters associated with clinical outcomes. Gene set enrichment and immune deconvolution analyses were performed. Weighted gene co-expression network analysis was employed for unsupervised identification of gene networks in each cluster. KEY FINDINGS AND LIMITATIONS: Five molecular clusters with distinct clinical outcomes were identified. Favorable subtypes (C1 and C2) were characterized by a luminal-like signature and an immunologically depleted tumor microenvironment (TME). Subtype C3 was characterized by FGFR3 alterations and a higher tumor mutational burden, and included all tumors with microsatellite instability. Despite higher rates of recurrence and inferior survival, subtypes C4 and C5 harbored an immunologically rich TME favoring response to ICB. Limitations include extrapolation of molecular features of tumors from the primary site to determine response to systemic immunotherapy and the limited resolution of bulk sequencing to distinguish gene expression in the tumor, stroma, and immune compartments. CONCLUSIONS AND CLINICAL IMPLICATIONS: RNA sequencing identified previously underappreciated UTUC molecular heterogeneity and suggests that UTUC patients at the highest risk of metastatic recurrence following surgery include those most likely to benefit from perioperative ICB.
引用
- Kim K, Alam SM, Kuo F, et al. Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma. Eur Urol. 2024. PMID: 39550333. doi:10.1016/j.eururo.2024.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。